Netupitant-Palonosetron is the first approved fixed dose combination drug for the prevention of chemotherapy induced nausea and vomiting. Cancer is a leading cause of d**th worldwide, accounting nearly 1.4 million new cases in 2012. The most common type of cancer is lung cancer accounting about 1.59 million d**ths, globally. Other prominent cancers are liver cancer, breast cancer, stomach cancer, esophageal and stomach cancer. In 2012, nearly 8.2 million d**ths occurred from aforementioned indication, globally. Cancer can be treated by surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, precision medicine and stem cell transplantation. The most common treatment for cancer is chemotherapy; it uses d***s to k**l cancer cells that cause pain and other problems. Chemotherapy given before surgery and radiation therapy to make the tumor cell smaller is known as neo-adjuvant chemotherapy and chemotherapy given after treatment with surgery or radiation therapy is known as adjuvant chemotherapy.Netupitant-Palonosetron FDC Market: Drivers and Restrains
According to Word Health Organization, it is estimated that by 2030, about 23.6 million new cases of cancer will prevail worldwide. Netupitant-Palonosetron Fixed Dose Combination is expected to fulfill unmet needs of the chemotherapy-induced nausea and vomiting therapeutics market. The fixed dose combination studies has revealed positive results in clinical phase trials. The demand of this drug for better treatment option by physician and patients will drive the market. Intense research and development in cancer therapeutics, the rise in the incidence of cancer cases, increased preference toward chemotherapy for the treatment of cancer and the use of chemotherapy in combination with other cancer treatment are anticipated to fuel the growth of Netupitant-Palonosetron FDC Market.
Netupitant-Palonosetron FDC Market: Regional Overview
Region-wise, the global Netupitant-Palonosetron FDCMarket is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. More than 70% of world's cancer d**th occurs in Africa, Asia, and South America. Around 33% of cancer cases worldwide are due to smoke and tobacco.
Netupitant-Palonosetron FDC Market: Key Players
The market leader for Netupitant-Palonosetron FDC Market is Helsinn Birex Pharmaceuticals Ltd and the drug is distributed and marketed by Eisai Inc.
Request Sample Report@ www.futuremarketinsights.com/reports/sample/rep-gb-3096/